Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 375

1.

[Impact of prenylation inhibition on RAS mutant tumors in preclinical studies].

Baranyi M, Molnár E, Rittler D, Hegedûs B, Tímár J.

Magy Onkol. 2019 Dec 9;63(4):320-329. Epub 2019 Oct 30. Hungarian.

2.

[Allele-specific inhibitors of mutant KRAS are in the focus of RASopathy consortium].

Nyíri K, Koppány G, Pálfy G, Vida I, Tóth S, Orgován Z, Ranðeloviæ I, Baranyi M, Molnár E, Keserû MG, Tóvári J, Perczel A, Vértessy BG, Tímár J.

Magy Onkol. 2019 Dec 9;63(4):310-323. Epub 2019 Nov 25. Hungarian.

3.

The Antitumor Effect of Lipophilic Bisphosphonate BPH1222 in Melanoma Models: The Role of the PI3K/Akt Pathway and the Small G Protein Rheb.

Rittler D, Baranyi M, Molnár E, Garay T, Jalsovszky I, Varga IK, Hegedűs L, Aigner C, Tóvári J, Tímár J, Hegedűs B.

Int J Mol Sci. 2019 Oct 3;20(19). pii: E4917. doi: 10.3390/ijms20194917.

4.

Synthetic enhancer compounds, besides acting on biogenic amine system, influence the glutamate transmission and stress response.

Knoll J, Zelena D, Timar J, Baghy K, Mervai Z, Miklya I.

Behav Brain Res. 2020 Jan 27;378:112290. doi: 10.1016/j.bbr.2019.112290. Epub 2019 Oct 11.

PMID:
31610214
5.

KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy.

Ghimessy AK, Gellert A, Schlegl E, Hegedus B, Raso E, Barbai T, Timar J, Ostoros G, Megyesfalvi Z, Gieszer B, Moldvay J, Renyi-Vamos F, Lohinai Z, Hoda MA, Klikovits T, Klepetko W, Laszlo V, Dome B.

Cancers (Basel). 2019 Oct 9;11(10). pii: E1514. doi: 10.3390/cancers11101514.

6.

[Predictive diagnostics of the programmed cell death receptor 1 (PD-1) - programmed cell death ligand 1 (PD-L1) inhibitory therapies].

Lotz G, Smuk G, Kocsmár É, Kocsmár I, Tímár J.

Magy Onkol. 2019 Sep 18;63(3):183-191. Epub 2019 Aug 30. Review. Hungarian.

7.

[Immunogenomic aspects of tumor progression].

Tímár J, Ladányi A.

Magy Onkol. 2019 Sep 18;63(3):173-182. Epub 2019 Aug 13. Review. Hungarian.

8.

Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression.

Molnár E, Garay T, Donia M, Baranyi M, Rittler D, Berger W, Tímár J, Grusch M, Hegedűs B.

Int J Mol Sci. 2019 Sep 11;20(18). pii: E4484. doi: 10.3390/ijms20184484.

9.

Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma.

Doma V, Kárpáti S, Rásó E, Barbai T, Tímár J.

BMC Cancer. 2019 Aug 29;19(1):853. doi: 10.1186/s12885-019-6048-8.

10.

Immunologic and immunogenomic aspects of tumor progression.

Ladányi A, Tímár J.

Semin Cancer Biol. 2019 Aug 13. pii: S1044-579X(19)30189-0. doi: 10.1016/j.semcancer.2019.08.011. [Epub ahead of print] Review.

PMID:
31419526
11.

Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma.

Doma V, Kárpáti S, Rásó E, Barbai T, Tímár J.

BMC Cancer. 2019 Aug 7;19(1):786. doi: 10.1186/s12885-019-5990-9. Erratum in: BMC Cancer. 2019 Aug 29;19(1):853.

12.

[Pathological diagnostics of CUP (Cancer of Unknown Primary)].

Tímár J.

Magy Onkol. 2019 Jun 21;63(2):67-74. Epub 2019 Mar 30. Review. Hungarian.

13.

PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.

Téglási V, Pipek O, Lózsa R, Berta K, Szüts D, Harkó T, Vadász P, Rojkó L, Döme B, Bagó AG, Tímár J, Moldvay J, Szállási Z, Reiniger L.

Clin Lung Cancer. 2019 Sep;20(5):363-369.e2. doi: 10.1016/j.cllc.2019.05.008. Epub 2019 May 15.

PMID:
31178388
14.

Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma.

Reiniger L, Téglási V, Pipek O, Rojkó L, Glasz T, Vágvölgyi A, Kovalszky I, Gyulai M, Lohinai Z, Rásó E, Tímár J, Döme B, Szállási Z, Moldvay J.

Acta Oncol. 2019 Aug;58(8):1087-1094. doi: 10.1080/0284186X.2019.1598575. Epub 2019 Apr 19.

PMID:
31002007
15.

Corrigendum to: Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.

Diossy M, Reiniger L, Sztupinszki Z, Krzystanek M, Timms KM, Neff C, Solimeno C, Pruss D, Eklund AC, Tóth E, Kiss O, Rusz O, Cserni G, Zombori T, Székely B, Kulka J, Tímár J, Csabai I, Szallasi Z.

Ann Oncol. 2019 Aug 1;30(8):1406. doi: 10.1093/annonc/mdz081. No abstract available.

16.

Clinical protein science in translational medicine targeting malignant melanoma.

Gil J, Betancourt LH, Pla I, Sanchez A, Appelqvist R, Miliotis T, Kuras M, Oskolas H, Kim Y, Horvath Z, Eriksson J, Berge E, Burestedt E, Jönsson G, Baldetorp B, Ingvar C, Olsson H, Lundgren L, Horvatovich P, Murillo JR, Sugihara Y, Welinder C, Wieslander E, Lee B, Lindberg H, Pawłowski K, Kwon HJ, Doma V, Timar J, Karpati S, Szasz AM, Németh IB, Nishimura T, Corthals G, Rezeli M, Knudsen B, Malm J, Marko-Varga G.

Cell Biol Toxicol. 2019 Aug;35(4):293-332. doi: 10.1007/s10565-019-09468-6. Epub 2019 Mar 21.

17.

[Molecular pathology of prostate cancer].

Tímár J.

Magy Onkol. 2019 Mar 19;63(1):5-9. Epub 2019 Jan 2. Review. Hungarian.

18.

Experimental Evidence for Transverse Wobbling in ^{105}Pd.

Timár J, Chen QB, Kruzsicz B, Sohler D, Kuti I, Zhang SQ, Meng J, Joshi P, Wadsworth R, Starosta K, Algora A, Bednarczyk P, Curien D, Dombrádi Z, Duchêne G, Gizon A, Gizon J, Jenkins DG, Koike T, Krasznahorkay A, Molnár J, Nyakó BM, Paul ES, Rainovski G, Scheurer JN, Simons AJ, Vaman C, Zolnai L.

Phys Rev Lett. 2019 Feb 15;122(6):062501. doi: 10.1103/PhysRevLett.122.062501.

19.

Selective Inhibition of HIF1α Expression by ZnSO4 Has Antitumoral Effects in Human Melanoma.

Burián Z, Ladányi A, Barbai T, Piurkó V, Garay T, Rásó E, Tímár J.

Pathol Oncol Res. 2019 Jan 6. doi: 10.1007/s12253-018-00573-1. [Epub ahead of print]

PMID:
30613921
20.

EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR Therapy.

Uhlyarik A, Piurko V, Vizkeleti L, Pápai Z, Rásó E, Lahm E, Kiss E, Sikter M, Vachaja J, Kenessey I, Tímár J.

Pathol Oncol Res. 2019 Jan 5. doi: 10.1007/s12253-018-00572-2. [Epub ahead of print]

PMID:
30612313
21.

New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort study.

Klikovits T, Lohinai Z, Fábián K, Gyulai M, Szilasi M, Varga J, Baranya E, Pipek O, Csabai I, Szállási Z, Tímár J, Hoda MA, Laszlo V, Hegedűs B, Renyi-Vamos F, Klepetko W, Ostoros G, Döme B, Moldvay J.

Lung Cancer. 2018 Dec;126:139-148. doi: 10.1016/j.lungcan.2018.11.004. Epub 2018 Nov 5.

PMID:
30527178
22.

Aquaporin-1 Protein Expression of the Primary Tumor May Predict Cerebral Progression of Cutaneous Melanoma.

Imrédi E, Liszkay G, Kenessey I, Plotár V, Gödény M, Tóth B, Fedorcsák I, Tímár J.

Pathol Oncol Res. 2018 Oct 30. doi: 10.1007/s12253-018-0513-6. [Epub ahead of print]

PMID:
30378011
23.

Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells.

Varga K, Hollósi A, Pászty K, Hegedűs L, Szakács G, Tímár J, Papp B, Enyedi Á, Padányi R.

BMC Cancer. 2018 Oct 23;18(1):1029. doi: 10.1186/s12885-018-4945-x.

24.

Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model.

Kenessey I, Kramer Z, István L, Cserepes MT, Garay T, Hegedűs B, Dobos J, Tímár J, Tóvári J.

Melanoma Res. 2018 Dec;28(6):536-546. doi: 10.1097/CMR.0000000000000488.

PMID:
30124539
25.

Neutron Skin Effects in Mirror Energy Differences: The Case of ^{23}Mg-^{23}Na.

Boso A, Lenzi SM, Recchia F, Bonnard J, Zuker AP, Aydin S, Bentley MA, Cederwall B, Clement E, de France G, Di Nitto A, Dijon A, Doncel M, Ghazi-Moradi F, Gadea A, Gottardo A, Henry T, Hüyük T, Jaworski G, John PR, Juhász K, Kuti I, Melon B, Mengoni D, Michelagnoli C, Modamio V, Napoli DR, Nyakó BM, Nyberg J, Palacz M, Timár J, Valiente-Dobón JJ.

Phys Rev Lett. 2018 Jul 20;121(3):032502. doi: 10.1103/PhysRevLett.121.032502.

PMID:
30085775
26.

Characterization of cellular and humoral immune responses to alkaline phosphatase from fertile hydatid cysts in the human peripheral blood.

Vatankhah A, Ghaffari SMR, Vatankhah RG, Piurkó V, Tímár J, Avan A, Jazayeri MH.

J Cell Physiol. 2019 Mar;234(3):2765-2777. doi: 10.1002/jcp.27092. Epub 2018 Aug 2.

PMID:
30073650
27.

[Genomics of neuroendocrine tumors of the lung and gastrointestinal tract: similarities and differences].

Tímár J, Patócs A.

Magy Onkol. 2018 Jul 20;62(2):77-82. Epub 2018 May 10. Review. Hungarian.

28.

Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.

Diossy M, Reiniger L, Sztupinszki Z, Krzystanek M, Timms KM, Neff C, Solimeno C, Pruss D, Eklund AC, Tóth E, Kiss O, Rusz O, Cserni G, Zombori T, Székely B, Tímár J, Csabai I, Szallasi Z.

Ann Oncol. 2018 Sep 1;29(9):1948-1954. doi: 10.1093/annonc/mdy216. Erratum in: Ann Oncol. 2019 Mar 30;:.

29.

The role of lipid signaling in the progression of malignant melanoma.

Tímár J, Hegedüs B, Rásó E.

Cancer Metastasis Rev. 2018 Sep;37(2-3):245-255. doi: 10.1007/s10555-018-9729-x. Review.

PMID:
29808460
30.

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.

Molnár E, Rittler D, Baranyi M, Grusch M, Berger W, Döme B, Tóvári J, Aigner C, Tímár J, Garay T, Hegedűs B.

BMC Cancer. 2018 May 8;18(1):542. doi: 10.1186/s12885-018-4455-x.

31.

Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.

Rojkó L, Reiniger L, Téglási V, Fábián K, Pipek O, Vágvölgyi A, Agócs L, Fillinger J, Kajdácsi Z, Tímár J, Döme B, Szállási Z, Moldvay J.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1219-1226. doi: 10.1007/s00432-018-2642-4. Epub 2018 Apr 19.

PMID:
29675791
32.

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Bremmer F, Gaisa NT, Chlosta P, Kriegsmann J, Kovalszky I, Timar J, Kristiansen G, Radzun HJ, Knüchel R, Schuler M, Black PC, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BWG, Nyirády P, Szarvas T.

Int J Cancer. 2018 Oct 1;143(7):1764-1773. doi: 10.1002/ijc.31547. Epub 2018 May 10.

33.

NSCLC molecular testing in Central and Eastern European countries.

Ryska A, Berzinec P, Brcic L, Cufer T, Dziadziuszko R, Gottfried M, Kovalszky I, Olszewski W, Oz B, Plank L, Timar J.

BMC Cancer. 2018 Mar 9;18(1):269. doi: 10.1186/s12885-018-4023-4.

34.

Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharygeal, and Hypopharyngeal Cancer.

Birtalan E, Danos K, Gurbi B, Brauswetter D, Halasz J, Kalocsane Piurko V, Acs B, Antal B, Mihalyi R, Pato A, Fent Z, Polony G, Timar J, Tamas L.

Appl Immunohistochem Mol Morphol. 2018 Aug;26(7):e79-e85. doi: 10.1097/PAI.0000000000000590.

PMID:
29271789
35.

The phosphomimetic mutation of syndecan-4 binds and inhibits Tiam1 modulating Rac1 activity in PDZ interaction-dependent manner.

Keller-Pinter A, Ughy B, Domoki M, Pettko-Szandtner A, Letoha T, Tovari J, Timar J, Szilak L.

PLoS One. 2017 Nov 9;12(11):e0187094. doi: 10.1371/journal.pone.0187094. eCollection 2017.

36.

[Molecular diagnostics of ALK-positive lung cancer].

Tímár J, Lotz G, Rásó E, Moldvay J.

Magy Onkol. 2017 Sep 20;61(3):301-311. Epub 2017 Aug 1. Review. Hungarian.

37.

RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data.

Kafatos G, Niepel D, Lowe K, Jenkins-Anderson S, Westhead H, Garawin T, Traugottová Z, Bilalis A, Molnar E, Timar J, Toth E, Gouvas N, Papaxoinis G, Murray S, Mokhtar N, Vosmikova H, Fabian P, Skalova A, Wójcik P, Tysarowski A, Barugel M, van Krieken JH, Trojan J.

Biomark Med. 2017 Sep;11(9):751-760. doi: 10.2217/bmm-2016-0358. Epub 2017 Jul 27.

38.

Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca2+ Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK.

Hegedüs L, Padányi R, Molnár J, Pászty K, Varga K, Kenessey I, Sárközy E, Wolf M, Grusch M, Hegyi Z, Homolya L, Aigner C, Garay T, Hegedüs B, Tímár J, Kállay E, Enyedi Á.

Front Oncol. 2017 May 24;7:95. doi: 10.3389/fonc.2017.00095. eCollection 2017.

39.

[Predictive markers of immunotherapy of cancer, practical issues of PD-L1 testing].

Tímár J, Ladányi A.

Magy Onkol. 2017 Jun 6;61(2):158-166. Epub 2017 May 5. Review. Hungarian.

40.

Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis.

Téglási V, Reiniger L, Fábián K, Pipek O, Csala I, Bagó AG, Várallyai P, Vízkeleti L, Rojkó L, Tímár J, Döme B, Szállási Z, Swanton C, Moldvay J.

Neuro Oncol. 2017 Aug 1;19(8):1058-1067. doi: 10.1093/neuonc/now309.

41.

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis.

Lohinai Z, Klikovits T, Moldvay J, Ostoros G, Raso E, Timar J, Fabian K, Kovalszky I, Kenessey I, Aigner C, Renyi-Vamos F, Klepetko W, Dome B, Hegedus B.

Sci Rep. 2017 Jan 4;7:39721. doi: 10.1038/srep39721.

42.

The evidence for and against different modes of tumour cell extravasation in the lung: diapedesis, capillary destruction, necroptosis, and endothelialization.

Paku S, Laszlo V, Dezso K, Nagy P, Hoda MA, Klepetko W, Renyi-Vamos F, Timar J, Reynolds AR, Dome B.

J Pathol. 2017 Mar;241(4):441-447. doi: 10.1002/path.4855. Epub 2017 Jan 27.

PMID:
28026875
43.

p16INK4 expression is of prognostic and predictive value in oropharyngeal cancers independent of human papillomavirus status: a Hungarian study.

Brauswetter D, Birtalan E, Danos K, Kocsis A, Krenacs T, Timar J, Mihalyi R, Horcsik D, Polony G, Tamas L, Petak I.

Eur Arch Otorhinolaryngol. 2017 Apr;274(4):1959-1965. doi: 10.1007/s00405-016-4412-8. Epub 2016 Dec 20.

PMID:
27999998
44.

Comparison of immunophenotypes of primary breast carcinomas and multiple corresponding distant metastases: an autopsy study of 25 patients.

Szekely B, Nagy ZI, Farago Z, Kiss O, Lotz G, Kovacs KA, Madaras L, Udvarhelyi N, Dank M, Szentmartoni G, Baranyai Z, Harsanyi L, Tőkés AM, Timar J, Szasz AM, Kulka J.

Clin Exp Metastasis. 2017 Jan;34(1):103-113. doi: 10.1007/s10585-016-9830-x. Epub 2016 Nov 24.

PMID:
27885435
45.

KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.

Kenessey I, Kói K, Horváth O, Cserepes M, Molnár D, Izsák V, Dobos J, Hegedűs B, Tóvári J, Tímár J.

Oncotarget. 2016 Nov 29;7(48):79503-79514. doi: 10.18632/oncotarget.12806.

46.

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.

Módos O, Reis H, Niedworok C, Rübben H, Szendröi A, Szász MA, Tímár J, Baghy K, Kovalszky I, Golabek T, Chlosta P, Okon K, Peyronnet B, Mathieu R, Shariat SF, Hollósi P, Nyirády P, Szarvas T.

Oncotarget. 2016 Jun 28;7(26):39293-39301. doi: 10.18632/oncotarget.9828.

47.

Significance of Primary Tumor Location and Histology for Brain Metastasis Development and Peritumoral Brain Edema in Lung Cancer.

Fábián K, Gyulai M, Furák J, Várallyay P, Jäckel M, Bogos K, Döme B, Pápay J, Tímár J, Szállási Z, Moldvay J.

Oncology. 2016;91(5):237-242. Epub 2016 Aug 26.

PMID:
27562339
48.

Inhibition of α2A-Adrenoceptors Ameliorates Dextran Sulfate Sodium-Induced Acute Intestinal Inflammation in Mice.

Zádori ZS, Tóth VE, Fehér Á, Al-Khrasani M, Puskár Z, Kozsurek M, Timár J, Tábi T, Helyes Z, Hein L, Holzer P, Gyires K.

J Pharmacol Exp Ther. 2016 Sep;358(3):483-91. doi: 10.1124/jpet.116.235101. Epub 2016 Jul 14.

PMID:
27418171
49.

Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.

Szendrői A, Szász AM, Kardos M, Tőkés AM, Idan R, Szűcs M, Kulka J, Nyirády P, Szendrői M, Szállási Z, Győrffy B, Tímár J.

Oncotarget. 2016 Jul 5;7(27):42086-42098. doi: 10.18632/oncotarget.9669.

50.

Genetic progression of malignant melanoma.

Tímár J, Vizkeleti L, Doma V, Barbai T, Rásó E.

Cancer Metastasis Rev. 2016 Mar;35(1):93-107. doi: 10.1007/s10555-016-9613-5. Review.

PMID:
26970965

Supplemental Content

Support Center